GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xcorporeal Inc (GREY:XCRP) » Definitions » Cash Conversion Cycle

Xcorporeal (Xcorporeal) Cash Conversion Cycle : 0.00 (As of Sep. 2009)


View and export this data going back to . Start your Free Trial

What is Xcorporeal Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Xcorporeal's Days Sales Outstanding for the three months ended in Sep. 2009 was 0.
Xcorporeal's Days Inventory for the three months ended in Sep. 2009 was 0.
Xcorporeal's Days Payable for the three months ended in Sep. 2009 was 0.
Therefore, Xcorporeal's Cash Conversion Cycle (CCC) for the three months ended in Sep. 2009 was 0.00.


Xcorporeal Cash Conversion Cycle Historical Data

The historical data trend for Xcorporeal's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xcorporeal Cash Conversion Cycle Chart

Xcorporeal Annual Data
Trend Feb99 Feb00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xcorporeal Quarterly Data
Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Xcorporeal's Cash Conversion Cycle

For the Medical Devices subindustry, Xcorporeal's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xcorporeal's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xcorporeal's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Xcorporeal's Cash Conversion Cycle falls into.



Xcorporeal Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Xcorporeal's Cash Conversion Cycle for the fiscal year that ended in Dec. 2008 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=0+0-0
=0.00

Xcorporeal's Cash Conversion Cycle for the quarter that ended in Sep. 2009 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=0+0-0
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xcorporeal  (GREY:XCRP) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Xcorporeal Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Xcorporeal's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Xcorporeal (Xcorporeal) Business Description

Traded in Other Exchanges
N/A
Address
80 Empire Drive, Lake Forest, CA, USA, 92630
Website
Xcorporeal Inc is a medical device company, developing an innovative extra-corporeal platform technology to be used in devices to replace the function of various human organs.
Executives
Kelly J. Mccrann director, officer: Chairman and CEO 11150 SANTA MONICA BLVD #1500, LOS ANGELES CA 90025
Daniel S Goldberger officer: Chief Executive Officer 24 CARPENTER ROAD, CHESTER NY 10918
Marc G Cummins director C/O PRIME LOGIC CAPITAL, LLC, 135 EAST 57TH STREET, 11TH FLOOR, NEW YORK NY 10022
Prime Logic Capital, Llc 10 percent owner 135 EAST 57TH STREET, 11TH FLOOR, NEW YORK NY 10022
Robert Weinstein officer: Chief Financial Officer 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Terren S Peizer director, 10 percent owner, officer: Executive Chairman 11111 SANTA MONICABLVD STE.500, LOS ANGELES CA 90025
Jay Wolf director 981 LINDA FLORA DRIVE, LOS ANGELES, CA 90049
Herve De Kergrohen director 22 CHEMIN DU NANTET, COLLONGE-BELLERIVE V8 CH1245
Nicholas Sheridan Lewin director 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Lawrence Lacerte 10 percent owner C/O TERAGLOBAL COMMUNICATIONS CORP, 9171 TOWNE CENTRE DRIVE SUITE 600, SAN DIEGO CA 92122

Xcorporeal (Xcorporeal) Headlines